Clinical trial
An Open-label, Multicenter, Multinational Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Acid Alpha-glucosidase Treatment in Patients Less Than 6 Months Old With Infantile-onset Pompe Disease
NCT00059280 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multicenter, Multinational Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Acid Alpha-glucosidase Treatment in Patients Less Than 6 Months Old With Infantile-onset Pompe Disease
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- April 30, 2003
- Completion date
- September 30, 2005
- Enrollment
- 16 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.